最近搜索：細(xì)胞培養(yǎng) 微生物學(xué) 分子生物 生物化學(xué)
首頁>>免疫學(xué)>>一抗>>人類乳頭狀瘤病毒16-E7抗體
人類乳頭狀瘤病毒16-E7抗體
  • 產(chǎn)品貨號：
    BN41635R
  • 中文名稱：
    人類乳頭狀瘤病毒16-E7抗體
  • 英文名稱：
    Rabbit anti-HPV16 E7 Polyclonal antibody
  • 品牌：
    Biorigin

  • 貨號

    產(chǎn)品規(guī)格

    售價

    備注

  • BN41635R-50ul

    50ul

    ￥1486.00

    交叉反應(yīng)：HPV16,Human 推薦應(yīng)用：WB,IHC-P,IHC-F,ICC,IF,Flow-Cyt,ELISA

  • BN41635R-100ul

    100ul

    ￥2360.00

    交叉反應(yīng)：HPV16,Human 推薦應(yīng)用：WB,IHC-P,IHC-F,ICC,IF,Flow-Cyt,ELISA

  • BN41635R-200ul

    200ul

    ￥3490.00

    交叉反應(yīng)：HPV16,Human 推薦應(yīng)用：WB,IHC-P,IHC-F,ICC,IF,Flow-Cyt,ELISA

產(chǎn)品描述

英文名稱HPV16 E7
中文名稱人類乳頭狀瘤病毒16-E7抗體
別    名E7; HPV16 E7 protein; Human Papilloma Virus; Human papillomavirus type 16 E7; Human papillomavirus type 16 E7; Protein E7; Human Papillomavirus 16 (E7); HPV16 E7; E7 protein (HPV16); VE7_HPV16; HPV16-E7. 


研究領(lǐng)域腫瘤  
抗體來源Rabbit
克隆類型Polyclonal
交叉反應(yīng)Human, 
產(chǎn)品應(yīng)用ELISA=1:5000-10000 IHC-P=1:100-500 IHC-F=1:100-500 Flow-Cyt=1ug/Test ICC=1:100-500 IF=1:100-500 （石蠟切片需做抗原修復(fù)）
not yet tested in other applications.
optimal dilutions/concentrations should be determined by the end user.
分 子 量60kDa
細(xì)胞定位細(xì)胞核 
性    狀Liquid
濃    度1mg/ml
免 疫 原KLH conjugated synthetic peptide derived from human HPV16 E7:21-98/98 
亞    型IgG
純化方法affinity purified by Protein A
儲 存 液0.01M TBS(pH7.4) with 1% BSA, 0.03% Proclin300 and 50% Glycerol.
保存條件Shipped at 4℃. Store at -20 °C for one year. Avoid repeated freeze/thaw cycles.
PubMedPubMed
產(chǎn)品介紹Human papilloma viruses (HPVs) can be classified as either high risk or low risk according to their association with cancer. HPV16 and HPV18 are the most common of the high risk group while HPV6 and HPV11 are among the low risk types. Approximately 90% of cervical cancers contain HPV DNA of the high risk types. Mutational analysis have shown that the E6 and E7 genes of the high risk HPVs are necessary and sufficient for HPV transforming function. The specific interactions of the E6 and E7 proteins with p53 and pRB, respectively, correlate with HPV high and low risk classifications. The high risk HPV E7 proteins bind to pRB with a higher affinity than do the low risk HPV proteins, and only the high risk HPV E6 proteins form detectable complexes with p53 in vitro.

Function:
E7 protein has both transforming and trans-activating activities. Disrupts the function of host retinoblastoma protein RB1/pRb, which is a key regulator of the cell cycle. Induces the disassembly of the E2F1 transcription factors from RB1, with subsequent transcriptional activation of E2F1-regulated S-phase genes. Inactivation of the ability of RB1 to arrest the cell cycle is critical for cellular transformation, uncontrolled cellular growth and proliferation induced by viral infection. Stimulation of progression from G1 to S phase allows the virus to efficiently use the cellular DNA replicating machinery to achieve viral genome replication. Interferes with histone deacetylation mediated by HDAC1 and HDAC2, leading to activation of transcription.

Subunit:
Homodimer. Homooligomer. Interaction with host RB1 induces the aberrant dissociation of RB1-E2F1 complex thereby disrupting RB1's activity. Binds to CHD3 through its zinc-finger domain. Forms a complex with CHD3 and HDAC1, thereby altering the action of host histone deacetylation. A similar complex involving E7, CHD3 and HDAC2 might also form. Interacts with E2; this interaction inhibits E7 oncogenic activity.

Similarity:
Belongs to the papillomaviridae E7 protein family.

SWISS:
P03129

Gene ID:
1489079

Database links:

Entrez Gene: 1489079 HPV16

SwissProt: P03129 HPV16




Important Note:
This product as supplied is intended for research use only, not for use in human, therapeutic or diagnostic applications.